Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kelsey Goodwin
PIPR
Kelsey Goodwin
Piper Sandler
Wall Street Analyst
★★★☆☆
#1210
on 13Foresight · ranked by our own returns
57%
Success Rate
+16.5%
Average Return
12 of 21 calls profitable · +7.0% vs benchmark
📈 Across the calls we could measure, roughly 57% of Kelsey Goodwin's ratings turned a profit when each position was held for 1 year — averaging +16.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

66 Buy 7 Hold 0 Sell
Kelsey's Stock Coverage 21 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
NUVL
Nuvalent
 Jun 09, 2026 HOLD Buy
-0.3% avg upside
21 analysts
$124.00
0.48% Upside
 +0.1%
LONA
LeonaBio
 May 27, 2026 BUY Buy
+13.9% avg upside
9 analysts
$20.00
144.59% Upside
 ·
TARA
Protara Therapeutics
 May 20, 2026 BUY Strong Buy
+1153.9% avg upside
21 analysts
$24.00
503.08% Upside
 -18.1%
TNGX
Tango Therapeutics
 May 15, 2026 HOLD Strong Buy
+24.2% avg upside
14 analysts
$24.00
14.27% Downside
 +57.0%
RLMD
Relmada Therapeutics
 May 13, 2026 BUY Buy
+106.4% avg upside
15 analysts
$12.00
78.31% Upside
 -14.9%
ERAS
Erasca
 May 12, 2026 BUY Strong Buy
+38.6% avg upside
14 analysts
$18.00
31.70% Upside
 +34.7%
JANX
Janux Therapeutics Inc
 May 08, 2026 BUY Strong Buy
+217.9% avg upside
21 analysts
$26.00
82.76% Upside
 -0.2%
RVMD
Revolution Medicines
 May 07, 2026 BUY Strong Buy
-12.2% avg upside
32 analysts
$172.00
5.49% Upside
 +10.7%
ORIC
Oric Pharmaceuticals
 May 05, 2026 BUY Strong Buy
+180.1% avg upside
19 analysts
$22.00
159.19% Upside
 -13.6%
SMMT
Summit Therapeutics
 May 01, 2026 HOLD Strong Buy
+112.6% avg upside
27 analysts
$16.00
16.36% Upside
 -13.9%
OLMA
Olema Pharmaceuticals
 Apr 20, 2026 BUY Strong Buy
+303.7% avg upside
16 analysts
$40.00
320.66% Upside
 -44.6%
URGN
Urogen Pharma
 Apr 20, 2026 BUY Strong Buy
+13.4% avg upside
16 analysts
$40.00
19.15% Upside
 +31.7%
ENGN
enGene Holdings
 Mar 26, 2026 BUY Buy
+478.3% avg upside
13 analysts
 — -74.9%
CGON
CG Oncology, Inc.
 Mar 26, 2026 BUY Strong Buy
+41.1% avg upside
17 analysts
 — -8.4%
BDTX
Black Diamond Therapeutics
 Mar 17, 2026 BUY Strong Buy
+987.8% avg upside
12 analysts
$8.00
381.90% Upside
 +23.3%
BCAX
Bicara Therapeutics Inc.
 Dec 08, 2025 BUY Strong Buy
+34.2% avg upside
14 analysts
$36.00
54.87% Upside
 +21.3%
IPSC
Century Therapeutics
 May 15, 2025 BUY Strong Buy
+132.9% avg upside
11 analysts
$5.00
118.42% Upside
 +352.6%
GNLX
Genelux Corp.
 May 07, 2025 BUY Strong Buy
+513.8% avg upside
7 analysts
$8.00
169.84% Upside
 +22.0%
IOVA
Iovance Biotherapeutics
 Apr 01, 2025 HOLD Strong Buy
+225.4% avg upside
24 analysts
 — +6.2%
MGNX
MacroGenics
 Jul 30, 2024 HOLD Buy
+326.4% avg upside
25 analysts
 — -70.7%
LEGN
Legend Biotech
 Oct 31, 2022 HOLD Strong Buy
+134.2% avg upside
27 analysts
 — +32.6%
🔒 16 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kelsey Goodwin — Frequently Asked Questions
How accurate are Kelsey Goodwin's stock ratings?
Based on the calls 13Foresight could measure, about 57% of Kelsey's ratings were profitable over a one-year hold, with an average return of +16.5% per rating, or +7.0% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Kelsey ranked on 13Foresight?
Kelsey Goodwin is currently ranked #1210 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kelsey cover?
Kelsey most recently has ratings on NUVL, LONA, TARA, TNGX, RLMD, ERAS, JANX, RVMD, ORIC, SMMT, OLMA, URGN and 9 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.